Ironwood Q1 net loss $37.4M; revenue down 45% YoY; raises adjusted EBITDA guidance to >$105M

IRONWOOD PHARMACEUTICALS INC

2025-Q1 EPS reported -$0.23 revenue$41,143,000

Total revenue of $41.1M vs $74.9M in Q1 2024, down 45% YoY.
GAAP net loss $37.4M ($0.23 loss per share) vs $4.2M loss a year ago.
Adjusted EBITDA guidance raised to >$105M for FY 2025; on track to meet full-year guidance.
LINZESS prescription demand grew 8% YoY in Q1 2025, in line with expectations.
Company is exploring strategic alternatives to maximize stockholder value.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.